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Expression and localization of 
CB1R, NAPE-PLD, and FAAH in the 
vervet monkey nucleus accumbens
Ryan Kucera1, Joseph Bouskila1,3,4, Laurent Elkrief1,2, Anders Fink-Jensen5, Roberta Palmour3,4, 
Jean-François Bouchard  1 & Maurice Ptito1,4,5
Extensive rodent literature suggests that the endocannabinoid (eCB) system present in the nucleus 
accumbens (NAc) modulates dopamine (DA) release in this area. However, expression patterns of 
the cannabinoid receptor type 1 (CB1R), the synthesizing enzyme N-acyl phosphatidylethanolamine 
phospholipase D (NAPE-PLD), and the degradation enzyme fatty acid amide hydrolase (FAAH) in 
the NAc have not yet been described in non-human primates. The goal of this study is therefore to 
characterize the expression and localization of the eCB system within the NAc of vervet monkeys 
(Chlorocebus sabaeus) using Western blots and immunohistochemistry. Results show that CB1R, NAPE-
PLD, and FAAH are expressed across the NAc rostrocaudal axis, both in the core and shell. CB1R, NAPE-
PLD, and FAAH are localized in medium spiny neurons (MSNs) and fast-spiking GABAergic interneurons 
(FSIs). Dopaminergic projections and astrocytes did not express CB1R, NAPE-PLD, or FAAH. These data 
show that the eCB system is present in the vervet monkey NAc and supports its role in the primate brain 
reward circuit.
The endocannabinoid (eCB) system is widely expressed in the central nervous system (CNS). It comprises the 
cannabinoid receptors type 1 (CB1R) and type 2 (CB2R), endogenous ligands (eCBs), and enzymes regulating 
the levels of eCBs1–3. The eCBs are lipophilic molecules that are synthesized “on demand” from the membrane 
of postsynaptic neurons after an increase in neural activity and calcium ion influx1. These endogenous ligands 
function as fast acting retrograde neuromodulators and are degraded rapidly1. The synthesis of anandamide, an 
eCB, is in part mediated by the release of N-acylethanolamines (NAEs) from N-acyl phosphatidylethanolamine 
(NAPE), by enzymes such as N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD)4. Its swift deg-
radation is mostly mediated by the intracellular enzyme fatty acid amide hydrolase (FAAH)5,6. The expression 
of CB1R is found in many structures of the mouse, rat, monkey, and human brain, including the amygdala, cin-
gulate cortex, prefrontal cortex (PFC), ventral pallidum, caudate, putamen, nucleus accumbens (NAc), ventral 
tegmental area (VTA) and lateral hypothalamus7–10. These regions are involved in reward, addiction and cognitive 
function. CB1R is also localized throughout the neocortex in rodents and primates11–13.
Neurophysiological studies first demonstrated that cannabis exerts its addictive potential from activating the 
pleasure-reward circuitry of the brain, namely the VTA that synapses with the NAc14. NAc dopamine (DA) ele-
vation is qualitatively indistinguishable whether it is produced by THC, opioids, amphetamine, cocaine, ethanol, 
nicotine, barbiturates, or addictive dissociative anesthetics such as phencyclidine15,16. The prevalence of treatment 
for cannabis dependence is greater than treatment for cocaine addiction in the USA17, and its addiction potential 
has been further demonstrated by self-administration of THC in squirrel monkeys17. Within the NAc, there is 
a functional dissociation of the effect of VTA DA release onto the shell and core. The shell mediates feelings of 
reward while the core mediates locomotion toward rewards18,19 through a motor circuit that includes the substan-
tia nigra (SN)20. While it is known that the eCB system may influence these circuits, the detailed anatomy of eCB 
system components in these circuits has not yet been fully described.
Recent investigations have intensified efforts on the localization of an endogenous cannabinoid system in the 
NAc. CB1R is localized in the NAc of rodents11,21,22, and is moderately expressed in the rat NAc23. It is also found 
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in fast-spiking GABAergic interneurons (FSIs) in the NAc of mice24 and is expressed by GABAergic interneu-
rons in the rat NAc25, but not in cholinergic or somatostatin-positive neurons in the rat NAc25 or dopaminergic 
neurons in the basal ganglia of rats7. In the rat NAc, CB1R is present on GABAergic medium spiny neurons 
(MSNs)26,27, and is also expressed in the mouse on the terminals of glutamatergic prefrontal cortical projecting 
neurons28,29. It has been proposed that cannabinoid receptors found on glutamatergic and GABAergic neurons 
modulate the activity of VTA DA neurons that project to the NAc30. Additionally, the SN has dopaminergic pro-
jections onto the NAc core20 which may be similarly modulated. In the rat, the SN receives GABAergic projections 
from CB1R containing neurons in the NAc27, suggesting an eCB role in the encoding of reward-related motor 
programs. The presence of CB1R has also been detected in the primate NAc10, but not thoroughly investigated.
NAPE-PLD and FAAH distributions in the monkey NAc remain both unknown since all detailed immunohis-
tochemical studies available to date have been carried out in rodents. NAPE-PLD plays a role in the rodent NAc 
signaling22, and FAAH antagonists increase DA levels therein both with and without anandamide31. Furthermore, 
a large body of evidence shows that the eCB system modulates the neural activity within the NAc14,30,32–34. Since 
the NAc is a key player in addiction in rodent models and it contains components of the eCB system, it has been 
proposed that the latter may be involved in the mediation of addictive behavior. There is, however, no available 
data for the primate NAc and it is therefore the aim of this study to examine the expression and the precise locali-
zation of the eCB system components, namely CB1R, NAPE-PLD, and FAAH, in the vervet monkey NAc.
For its part, the CB2R is best known to be highly expressed in the immune system, including in brain micro-
glia35, but more recently has been found at low levels in some neurons3. This includes the finding of CB2R genes 
and receptors to be expressed in mice midbrain DA neurons, and therein to effect DA neuronal firing and related 
behaviour36. However, its function in the CNS is not yet as well understood3 as CB1R on which the present 
investigation is focused. CB2R shares only 44% homology with CB1R37, and as a result functions significantly dif-
ferently. CB2R shows little modulation of calcium channels or inwardly rectifying potassium channels in compar-
ison to CB1R, which makes its signaling very different38. Its signaling is further complicated by species differences 
in CB2R response to identical drugs3. Despite common agonists, these receptors ultimately function differently. 
This is also reflected in differing affinity of their agonists. While 2-AG has high affinity at CB2R, anandamide 
serves as a weaker partial agonist of CB2R and has greater specificity to CB1R3. The significant difference in func-
tion of these two receptors makes them best studied separately. Here, the investigation of CB1R is complemented 
by the additional study of NAPE-PLD and FAAH, the synthesizing and degradative enzymes of anandamide.
Results
Western Blot Analysis. CB1R, NAPE-PLD, and FAAH presence and specificity in the NAc. We investigated 
the expression of three elements of the eCB system by evaluating the total amounts of CB1R and eCB-synthesiz-
ing (NAPE-PLD) and degradative (FAAH) enzymes in the monkey NAc. Immunoblots of three unfixed vervet 
NAc homogenates incubated with CB1R, NAPE-PLD, and FAAH antisera are shown in Fig. 1 and demonstrate 
their presence in the NAc. The specificity of the antibodies is shown by specific band recognition and blocking 
peptide signal abolishment. The CB1R blot recognized the expected major band at 60 kDa (Fig. 1a). The NAPE-
PLD immunoblot shows as expected an intense band at 46 kDa (Fig. 1b), and the FAAH blot shows a dense 
expected band at approximately 63 kDa (Fig. 1c). Pre-incubation with the respective blocking peptides for NAPE-
PLD and FAAH abolished the antibody signal for each (Fig. 1b,c), confirming the specificity of the antibody. 
However, for the CB1R antibody used here, a blocking peptide condition was not possible since there is not yet 
one commercially available. GAPDH loading controls for each immunoblot showed even levels of protein con-
tent across samples (n = 3) for each condition, as well as even loading between conditions with and without their 
respective blocking peptides. We provide here for the first time a set of results in primates that further extends the 
data obtained in rodents23.
DAB Single Labeling. Delineation of core and shell in the NAc. To verify the precise location of the bor-
der between the core and shell of the NAc, DAB (3,3′-diaminobenzidine) immunostaining was carried out for 
calbindin-d28k (CB), a calcium binding and buffering protein that shows lower expression in the shell than the 
core39. Coronal sections of basal forebrain were taken, and 6 evenly spaced slices at a time were selected from 
across the rostrocaudal extent (Fig. 2). The border between the core and shell has been visualized with overlaid 
Figure 1. Presence of CB1R, NAPE-PLD, or FAAH in the NAc of three vervet monkeys. WB analysis of total 
protein samples for the CB1R antibody (a) showing detection of the expected major protein band at 60 kDa. For 
the NAPE-PLD antibody (b), the expected band is seen at 46 kDa, and not detected when pre-incubated with 
its blocking peptide. For the FAAH antibody (c), the expected band is seen at 63 kDa, and not detected when 
pre-incubated with its blocking peptide. All lanes contained 10 µg of total protein. The lower blots show the 
expression of GAPDH and demonstrate loading in all lanes.
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dashed lines. The demarcation of core and shell in the vervet monkey was found to be highly similar to previ-
ously published work in the macaque monkey40. Confirmation of the core and shell borders throughout the NAc 
allowed us to accurately determine the position of the nucleus and these subdivisions during confocal microscopy 
of our immunofluorescent experiments.
The vervet NAc has an irregular ovoid shape that varies across the rostrocaudal axis. The core expands as it 
progresses to the middle of the structure, and then becomes smaller once again as it reaches its caudal portion, 
and finally stretches into a thin oval as it subsides towards the most caudal extent. The shell encapsulates the 
ventral portion of the core throughout, always lying nearest to the apex of the heart-shaped striatum. The shell is 
largest in the middle of the rostrocaudal axis. The ventromedial beginning of the division of the core and shell can 
at times be clearly seen by the nearby ventricle reaching between them, particularly in mid-rostrocaudal sections.
Spatial expression of the CB1R system in the NAc. To visualize the localization of the CB1R system in the 
NAc, coronal serial brain sections containing the NAc were labeled with specific antibodies against CB, CB1R, 
NAPE-PLD, or FAAH. In the negative control condition, no primary antibody was used. Serial sections were 
taken from six representative levels across the rostrocaudal axis to compare the patterns of distribution. CB 
delimited anatomically the border between the core and the shell (Fig. 2a–f), as a reference for the rest of the 
series of slices, which were labeled for CB1R, NAPE-PLD, or FAAH. CB1R was detected throughout the NAc, 
but with higher expression in the dorsomedial and ventral shell in middle and caudal sections (Fig. 3c–f). In the 
caudal portion of the NAc, greater expression in the core was also present (Fig. 3d–f). NAPE-PLD and FAAH 
were homogeneously expressed across the rostrocaudal extent of the NAc (Fig. 3g–r). At low magnification, the 
entire NAc can be clearly seen and the distribution of eCB components visualized relative to the demarcation of 
the shell and core by CB. A consistent staining pattern across all monkeys was found.
Figure 2. Photomicrographs of calbindin-stained coronal sections of basal forebrain across the rostrocaudal 
axis. (a–f) The first rostral section of the NAc was taken at approximately 3.5 mm anterior to the anterior 
commissure (AC) and the last caudal section was taken 0.3 mm anterior to the AC. The total length of the 
NAc was approximately 4 mm. Each slice distance relative to the AC is designated in the top right corner. The 
calbindin stain indicates the core and shell border of the NAc by overlaid dashed lines. The demarcation of 
core and shell is based on our own observation and previously published work39,40. Scale bar = 1 mm. C = core; 
Sh = shell.
Figure 3. Spatial distribution of CB1R, NAPE-PLD, and FAAH throughout the rostrocaudal extent of the 
NAc. Coronal serial sections were taken adjacent to the CB stained slices in Fig. 2(a–f) Rostral sections show 
relatively homogenous staining of CB1R, but there is an increase of staining density in the medial portion of 
the shell beginning in mid-rostrocaudal sections (c). In (d) and further caudally, the CB1R expression is further 
increased in the medial shell. It is also noticeably augmented in the core and the ventral shell at these levels. 
(g–l) NAPE-PLD and (m–r) FAAH distributions remain relatively homogenous across the rostrocaudal extent. 
Scale bar = 1 mm. C = core; Sh = shell.
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Immunofluorescent Double Labeling. CB1R, NAPE-PLD, and FAAH are expressed in medium spiny neu-
rons (MSNs). MSNs were marked with Ctip2, a transcription factor specific for their differentiation41. Double 
immunolabeling was performed against CB1R, NAPE-PLD, and FAAH (Fig. 4). The three CB1R system compo-
nents were all clearly expressed in the soma of Ctip2-positive neurons.
CB1R, NAPE-PLD, and FAAH are expressed in fast-spiking GABAergic interneurons (FSIs). The calcium binding 
protein PV was used to mark FSIs42,43. Double immunolabeling was performed against the CB1R system compo-
nents (Fig. 5). PV can be seen throughout perikarya and fibers, extending down to axons. The eCB components 
can be seen most clearly in the cell bodies.
CB1R, NAPE-PLD, and FAAH are not expressed in DA-producing cells. Tyrosine hydroxylase, the rate-limiting 
enzyme in DA synthesis, was used as a specific marker of dopaminergic neurons. No co-localization was obtained 
when sections were stained with TH and CB1R (Fig. 6). Axon fibers and terminals stained with TH surround 
the multiple cell bodies labeled with CB1R, suggesting a complementary but not overlapping staining pattern. 
Sections immuno-stained with TH and NAPE-PLD or FAAH showed similar patterns of complementation with-
out co-localization to that of TH with CB1R (Fig. 6). Lack of CB1R system expression in dopaminergic neurons 
is consistent with previous findings in rodents7.
CB1R, NAPE-PLD, and FAAH are not expressed in glial cells. Glial fibrillary acidic protein (GFAP) was used 
to mark astrocytes. CB1R, NAPE-PLD, and FAAH were not expressed in GFAP-positive glial cells in the NAc 
(Fig. 7). GFAP immunoreactivity was clearly detected; individual glial cell bodies and processes can be seen. 
While CB1R, NAPE-PLD, and FAAH were expressed in neurons, they did not co-localize with GFAP-positive 
cells (Fig. 7).
Discussion
This study reports for the first time the expression and localization of CB1R, NAPE-PLD, and FAAH in the NAc 
of vervet monkeys. Immunoblots of vervet monkey NAc tissue against CB1R, NAPE-PLD, and FAAH antisera 
were similar to those previously reported for rodents44,45 and vervet monkey retinal and thalamic tissues46,47. The 
NAc can be anatomically separated into two distinct parts: the outer shell and interior core48,49. Each part plays 
a different role in behavior and addiction50. The core is responsible for major output onto the SN, and receives 
all inputs from the SN, as well as some inputs from the VTA onto its medial portion20. The shell largely projects 
to the VTA51, though the SN also receives minor projections from the lateral shell. The shell also receives many 
projections back from the VTA52, mostly onto its medial and ventral portions20. We found differences in CB1R 
expression in the core and shell at diverse points along the rostrocaudal axis, with a higher dorsomedial and 
ventral expression in the shell in middle and caudal sections, and increased core expression in mid-rostrocaudal 
Figure 4. Double-label immunofluorescence illustrating co-localization of CB1R-IR, NAPE-PLD-IR, and 
FAAH-IR with Ctip2. Confocal micrographs of NAc co-immunolabeled for CB1R, NAPE-PLD, or FAAH 
(magenta), and Ctip2 (green), a specific marker for MSNs, in core and shell. Arrows point at Ctip2-positive 
MSNs that express either CB1R, NAPE-PLD, or FAAH. Scale bar = 10 µm.
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Figure 5. Double-label immunofluorescence illustrating co-localization of CB1R-IR, NAPE-PLD-IR, and 
FAAH-IR with parvalbumin (PV). Confocal micrographs of NAc co-immunolabeled for CB1R, NAPE-PLD, 
or FAAH (magenta), and PV (green), a specific marker for FSIs, in core and shell. Arrows point at PV-positive 
interneurons that express either CB1R, NAPE-PLD, or FAAH. Scale bar = 10 µm.
Figure 6. Double-label immunofluorescence illustrating co-localization of CB1R-IR, NAPE-PLD-IR, and 
FAAH-IR with tyrosine hydroxylase (TH). Confocal micrographs of NAc co-immunolabeled for CB1R, NAPE-
PLD, or FAAH (magenta), and TH (green), a specific marker for dopaminergic projections, in core and shell. 
Arrows point at TH-positive axons and terminals that do not express either CB1R, NAPE-PLD, or FAAH. Scale 
bar = 10 µm.
www.nature.com/scientificreports/
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sections of the NAc (Fig. 3). This may indicate a more pronounced role of eCBs in a circuit where the SN receives 
projections from the middle and caudal portion of the shell and the middle portion of the core. As for the VTA, 
the influence of eCBs stems from projections onto the middle portion of the NAc core, and its greater connections 
with the middle and caudal portions of the shell.
Recent research has shown that the NAc plays a key role in action selection; as such, abnormalities in accum-
bal signaling have been linked to the development of addictions and other neuropsychiatric conditions53,54. It 
has been hypothesized that DA transmission in the NAc is implicated in translating motivation into action55, 
and reinforcement learning56. Mesolimbic DA neurons projecting onto the NAc have two modes of firing, either 
“tonic” or “phasic”57,58, both of which are implicated in the development of drug addiction59. It has been reported 
that the eCB system plays a role in the modulation of both phasic and tonic DA firing in the NAc60. Although 
there seems to be moderate to low levels of CB1R in the NAc9,11,61,62, a collection of work has shown that the CB1R 
antagonists and agonists modulate DA NAc signaling, in both rodents and primates63,64. Additionally, CB1Rs in 
the monkey brain have been imaged in vivo using various radioligands65,66. CB1R is known to be responsible for 
the psychoactive effects of marijuana, the effects of which have been blocked by a CB1R antagonist in marijuana 
smoking humans67 and THC and anandamide self-administering monkeys17. This suggests the importance of 
CB1R in reward and addiction. CB2R might also play a role in the reward circuit. CB2R knockout mice have been 
shown to lack conditioned place preference for nicotine and to self-administer less nicotine68. A CB2R antagonist 
also blocked conditioned place preference from nicotine and reduced nicotine self-administration68. Interestingly, 
the CB2R agonist also reduced cocaine self-administration69. CB2R is also expressed in mouse VTA DA neu-
rons that have reduced excitability in the presence of CB2R agonists and reduced cocaine self-administration36. 
However, the role of the CB2R in the reward circuit and in neurons has not been studied in as much detail as the 
CB1R, and the CB2R remains better known for its critical role in immune function in the brain35. For these rea-
sons, we have focused our attention on describing the anatomy of CB1R expression in the NAc.
We have found that CB1R, NAPE-PLD, and FAAH are expressed in both cell bodies and processes in MSNs 
and FSIs, but not in dopaminergic projections or astrocytes. While it is well known that eCBs act as retrograde 
neuromodulators70, it has also been suggested that certain substrates, particularly anandamide, can act on CB1R 
postsynaptically or intrinsically71, or in an autocrine fashion72,73. Our results show the presence of CB1R in cell 
bodies, including on the cell membrane, which suggests that eCBs may also act as postsynaptic or autocrine 
modulators in the monkey NAc. This is further supported by the presence of CB1Rs in neuronal cell bodies and 
dendrites in the rat striatum27. Since the dopaminergic neurons which innervate the MSNs do not express the eCB 
system, any anterograde eCB modulation would likely come from FSIs or glutamatergic terminals from the PFC, 
though eCB spillover from nearby MSN or FSI dendrites is also possible74,75.
FSIs may act to synchronize the spike timing of larger populations of neurons76, such as MSNs. It has also been 
reported that FSIs may inhibit themselves77. The presence of the eCB system in FSIs suggests that it plays a role 
Figure 7. Double-label immunofluorescence illustrating co-localization of CB1R-IR, NAPE-PLD-IR, and 
FAAH-IR with glial fibrillary acidic protein (GFAP). Confocal micrographs of NAc co-immunolabeled for 
CB1R, NAPE-PLD, or FAAH (magenta), and GFAP (green), a specific marker for astrocytes, in core and 
shell. Arrows point at GFAP-positive glial cells that do not express either CB1R, NAPE-PLD, or FAAH. Scale 
bar = 10 µm.
www.nature.com/scientificreports/
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in how the spike timing of MSNs is regulated by FSIs, the decreased synchrony of which could lead to weaker 
inhibition of dopaminergic neurons in the VTA that project onto the NAc. Specific outputs of the NAc come from 
ensembles of neurons that are clustered spatially close to one another and fire in a coherent and synchronous 
manner, and require a strong excitatory input78, further supporting the importance of FSI synchronization of 
MSNs. The eCB system may also play a role in the gating of MSNs between their two possible resting potentials 
of a physiologically silent hyperpolarized “down” state and their slightly depolarized “up” state at which action 
potentials can be induced79. CB1R activation, whether on MSN cell bodies in the NAc or on MSN terminals in 
the VTA30 and SN27, may directly reduce inhibition of DA neuron firing in the NAc. Additionally, the presence of 
CB1Rs on NAc FSIs24, which are important for the synchronization of ensembles of MSNs, may further contribute 
to the regulation of MSN output80. CB1Rs have been detected on glutamatergic neurons terminating in the NAc in 
mice which suggest that they may also reduce MSN output29. Since some MSNs are also glutamatergic in addition 
to being GABAergic81, it may also be possible that CB1R affects glutamatergic signaling onto interneurons at the 
terminations of these MSN projections. Taken together, inhibition by CB1R activation on both GABAergic and 
glutamatergic cells may reduce the release of GABA by MSNs projecting onto VTA and SN DA neurons, which in 
turn may increase DA in the NAc and other brain regions. This dysregulation of DA release could enhance reward 
perception and motor pattern activation, underlying addiction. These results suggest that the eCB system may 
play a crucial role in the modulation of the primate brain reward circuit that remains to be investigated.
Materials and Methods
Animals. Ten vervet monkeys (Chlorocebus sabaeus) were used in this study (3 females and 7 males aged 
0.4 years (y), 0.5 y, 0.75 y, 2 y, 2 y, 2 y, 2.5 y, 3 y, 5.5 y, and 11 y). The animals were born and raised in an enriched 
environment in the laboratories of the Behavioral Sciences Foundation (BSF; St-Kitts, West Indies), a facility 
that is recognized by the Canadian Council on Animal Care (CCAC). The tissue samples used in this study 
were donated by the BSF and were part of a wider project approved by the ethics committee at the Université de 
Montréal (Comité de Déontologie de l′Expérimentation sur les Animaux, Ref number: 17-097). They were uti-
lized in accordance with the CCAC requirement for reduction of animals sacrificed for experimental purposes.
Tissue Preparation. Brain sections that included the whole NAc were prepared following previously pub-
lished methods46,47,82. Briefly, the animals were sedated with ketamine hydrochloride (10 mg/kg, i.m.), then eutha-
nized with an overdose of sodium pentobarbital (25 mg/kg, i.v.) and perfused transcardially with 0.1 M phosphate 
buffered saline (PBS, 0.1 M) until complete exsanguination. The brain was then either rapidly frozen unfixed for 
Western blots (WB), or was bathed in a 4% paraformaldehyde solution in PBS for immunohistochemistry. The 
fixed brain was then stereotaxically blocked, removed from the skull, weighed, and the volume determined. The 
brain was finally cryoprotected in graded sucrose solutions and embedded in Shandon embedding media at 
−65 °C. The blocks were sliced (40 µm) with a cryostat in a serial manner and stored, again according to previ-
ously published methods82.
Western Blotting. To test the presence and specificity of the CB1R, NAPE-PLD, and FAAH antisera, WB 
were performed on unfixed vervet NAc tissue from 3 different monkeys. The entire NAc from one hemisphere 
was dissected from each monkey and homogenized by hand using a sterile pestle in RIPA buffer (150 mM NaCl, 
20 mM Tris, pH 8.0, 1% NP-40 [USB Corp., Cleveland, OH, USA], 0.5% sodium deoxycholate, 0.1% SDS, 1 mM 
EDTA), supplemented with a protease-inhibitor mixture (aprotinin 1:1,000, leupeptin 1:1,000, pepstatin 1:1,000, 
and phenylmethylsulfonyl fluoride 0.2 mg/ml); Roche Applied Science, Laval, QC, Canada). After the samples 
were centrifuged (4 °C, 10 minutes), the supernatant was extracted and content was equalized using Thermo 
Scientific Pierce BCA Protein Assay Kit (Fisher Scientific, Ottawa, ON, Canada). Ten µg of protein per well was 
loaded in a 10% sodium dodecyl sulphate (SDS)-polyacrylamide gel and electrophoresed. It was then transferred 
onto a nitrocellulose membrane filter (BioTrace NTll; Life Sciences, Pall, Pensacola, FL, USA) and washed 3 
times 10 minutes in TBST (0.15 M NaCl, 25 mM Tris-HCl, 25 mM Tris, 0.5% Tween-20). It was blocked for an 
hour in 5% skim milk (Selection, Montreal, QC, Canada) in TBST, and left to incubate overnight in an IgG pri-
mary antibody raised in rabbit; anti-CB1R, anti-NAPE-PLD, and anti-FAAH at a concentration of 1:1,000 in 
blocking solution. For blocking peptide (BP) control conditions a ratio of 5:1 BP to antibody was pre-incubated 
for 1 hour before being diluted in blocking solution (final concentrations of NAPE-PLD 1:1,000, NAPE-PLD BP 
1:200; FAAH 1:1,000, FAAH BP 1:200). On the following day, 6 washes in TBST of 5 minutes each preceded and 
followed incubation of the blot in secondary antibody conjugated to horseradish peroxidase (1:5,000; Jackson 
Immunoresearch, West Grove, PA, USA) in blocking solution for two hours. The blot was washed 6 times 5 min-
utes in TBST. Detection was done using a homemade ECL WB detection reagent (final concentrations of 2.50 mM 
luminol, 0.4 mM p-coumaric acid, 0.1 M TrisHCl, pH 8.5, 0.018% H2O2). After detection, the loading control was 
performed. The blot was washed 3 times 10 minutes in TBST, blocked for an hour in 5% skim milk in TBST, then 
incubated overnight in an anti-GAPDH IgM primary antibody raised in mouse at a concentration of 1:20,000. 
The next day, the blot underwent the same washes, incubation in secondary antibody, washes again, and detec-
tion, as above.
DAB immunohistochemistry. DAB immunostaining was performed in free-floating solution similarly to 
previously published methods47. Briefly, brain sections of 40 μm that included the NAc were cleaned 3 times for 
10 minutes each in washing solution (0.1 M PBS buffer pH 7.4, 0.03% Triton X-100). The tissue was then protected 
from non-specific binding in a blocking solution (0.5% triton, 10% either normal donkey serum or normal goat 
serum, in 0.1 M PBS) for 90 minutes. The tissue was then placed in primary antibody (Table 1) diluted in block-
ing solution and left to incubate overnight at 4 °C. After washing the sections for 10 minutes once and 5 minutes 
twice in washing solution, the slides were incubated in secondary antibody (biotinylated goat anti-rabbit, donkey 
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anti-rabbit, or donkey anti-mouse diluted 1:200 in blocking solution) for 2 hours. Tissue was then washed 3 times 
for 10 minutes and incubated for 1 h in an avidin-biotin-conjugated horseradish peroxidase (Vectastain ABC kit, 
Burlingame, CA, USA) solution (1:500 in 0.1 M PBS). Another 3 washes of 10 minutes were performed and the 
sections were treated with a DAB substrate, until the tissue was coloured (1 to 10 minutes). The tissue was then 
washed again for 3 times of 10 minutes and the sections were mounted on gelatinized slides and left to dry. They 
then underwent dehydration in graded ethanol, were cleared in xylene, and cover slipped with Permount mount-
ing media (Fisher Scientific; Pittsburgh, PA, USA).
Immunofluorescence. Double-labeling were performed on the vervet monkey NAc, following previously 
published methods in the retina and dorsal lateral geniculate nucleus47,83, but with minor changes. Tissue was 
treated the same as in the above DAB protocol for “day one”, until primary antibody incubation. When the tis-
sue was ready to be incubated in primary antibody, it was exposed to two primary antibodies at dilution rates 
mentioned in Table 1 and incubated overnight. On the second day, the tissue was washed in washing solution for 
3 times 10 minutes. The tissue was then incubated in secondary antibody diluted in blocking solution (1:200). 
The slices were washed 3 times for 10 minutes in 0.1 M PBS, then 1 time for 10 minutes in 0.1 M PB. They were 
then mounted onto gelatinized slides and left to dry for approximately half an hour before coverslipping using 
Fluoromount G mounting medium (SouthernBiotech, Birmingham, AL, USA).
Equipment and Settings
Brightfield Microscopy. DAB slides were analyzed under a Leica microscope, using a 0.65X objective. The 
images were taken in Qcapture (Micro-Bright Field) software. All adjustments, such as size, colour, brightness 
and contrast, were performed using ImageJ and Adobe Photoshop (CS6; Adobe Systems; San Jose; CA, USA) and 
subsequently exported onto Adobe InDesign (CS6; Adobe Systems), where the final figure layout was completed.
Confocal Microscopy. Fluorescence was detected using a Leica TCS SP2 confocal laser scanning microscope 
with default Leica software (Leica Microsystems, Exton, PA, USA). Images were taken under a 63X objective, at 
resolutions of either 1080 × 1080 or 2160 × 2160 pixels. Green and far-red channels were used to detect images 
from the 40 µm slices. The green channel (488 nm) was used to detect cell markers and the far-red channels 
(647 nm) to detect CB1R, NAPE-PLD, and FAAH. To enhance some images, z-stacks were taken for optimization 
and averaged using ImageJ. Z-stacks allowed for visualization of cells along the X-Y, X-Z and Y-Z axes. All adjust-
ments, such as size, colour, brightness and contrast, were performed using ImageJ and Adobe Photoshop CS6 and 
subsequently exported onto Adobe InDesign CS6, where the final figure layout was completed.
Antibody Characterization (for more info, please see Table 1)
CB. A monoclonal mouse anti-calbindin-d28k (CB, Cell Signaling Technology, Danvers, MA, USA, Cat# 
13176, RRID: AB_2687400) was developed with a recombinant protein specific to the amino terminus of human 
CB. CB labels cell bodies, dendrites and their spines, and axons and their terminals, of MSNs in the basal ganglia 
of the monkey and rat, with the most intense labeling occurring in the matrix of the cytoplasm84. Primary anti-
body working dilutions and other detailed information are included in Table 1.
CB1R. A polyclonal rabbit anti-CB1R (CB1R, Calbiochem, Gibbstown, NJ, USA, Cat# 209550-100UL, RRID: 
AB_211563) was developed using the first 77 amino acid residues of rat CB1R. A major 60 kDa band in rat heart 
tissue85, and minor 23, 72 and 180 kDa bands from various other tissues (manufacturer data sheet) are recognized 
by this antibody. It has been previously reported that this antibody is specific, using a CB1R knockout mouse 
retina45. It recognizes CB1R in other species, including the vervet monkey46.
Antibody Immunogen Source Working Dilution RRID
CB Recombinant protein specific to amino terminus of human CB
Cell Signaling Technology, 
Danvers, MA, USA DAB 1:500, IF 1:200 AB_2687400
CB1R Fusion protein containing aa 1–77 of rat CB1R Calbiochem, Gibbstown, NJ, USA
DAB 1:300, IF 
1:200, WB 1:1,000 AB_211563
CTIP2 Synthetic peptide corresponding to aa 1–150 of human Ctip2 Abcam plc., Cambridge, UK IF 1:200 AB_2064130
FAAH Synthetic peptide corresponding to aa 561–579 of rat FAAH
Cayman Chemical, Ann 
Arbor, MI, USA
DAB 1:200, IF 
1:200, WB 1:1,000 AB_10078701
GFAP GFAP purified from pig spinal cord Cell Signaling Technology, Danvers, MA, USA IF 1:200 AB_561049
NAPE-PLD Synthetic peptide from human NAPE-PLD aa 159–172
Cayman Chemical, Ann 
Arbor, MI, USA
DAB 1:200, IF 
1:200, WB 1:1,000 AB_10507996
PV Parvalbumin purified from carp muscle Swant, Marly, Fribourg, Switzerland IF 1:200 AB_10000343
TH
TH purified from PC12 cells derived from rat 
pheochromocytoma; recognizes an epitope on 
the outside of the regulatory N-terminus of TH
EMD Millipore, Chemicon, 
Temecula, CA, USA IF 1:200 AB_2201528
Table 1. Primary antibodies used in this study. CB: Calbindin-d28k; CB1R: cannabinoid receptor type 1; CTIP2: 
CTIP2 transcription factor; DAB: 3,3′-diaminobenzidine immunostaining; FAAH: fatty acid amide hydrolase; 
GFAP: glial fibrillary acidic protein; IF: immunofluorescence; NAPE-PLD: N-acyl phosphatidylethanolamine-
specific phospholipase D; PV: parvalbumin; TH: tyrosine hydroxylase; WB: Western blot.
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CTIP2. A monoclonal rat anti-Ctip2 antibody (Ctip2, ab18465, Abcam plc., Cambridge, UK, Cat# ab18465, 
RRID: AB_2064130) was developed using a synthetic peptide corresponding to amino acid 1–150 of the human 
Ctip2. It is a specific marker of GABAergic medium-sized spiny neuron (MSN) differentiation, which com-
prises over 90% of striatal neurons, and is not present in interneurons41. This antibody’s use has been verified in 
primates86.
FAAH. A polyclonal rabbit anti-fatty acid amide hydrolase (FAAH, Cayman Chemical, Ann Arbor, MI, USA, 
Cat# 101600, RRID: AB_10078701) was developed using a synthetic peptide corresponding to amino acid 561–
579 of the rat FAAH. It recognizes a dense band at 63 kDa in FAAH recombinant protein (manufacturer data 
sheet). The antibody has been shown to have specificity in the vervet monkey46.
GFAP. A monoclonal mouse anti-glial fibrillary acidic protein (GFAP clone GA5, Cell Signaling Technology, 
Danvers, MA, USA, Cat# 3670, RRID: AB_561049) was purified using pig spinal cord GFAP. It is a specific marker 
of astrocytes, in humans, mice, and rats (manufacturer data sheet). Its specificity has also been verified by immu-
nofluorescence in the marmoset monkey brain87.
NAPE-PLD. A polyclonal rabbit anti-N-acyl phosphatidylethanolamine-specific phospholipase D 
(NAPE-PLD, Cayman Chemical, Ann Arbor, MI, USA, Cat# 10305, RRID: AB_10507996) was developed using 
part of a synthetic peptide from human NAPE-PLD. The amino acids (159–172), have been shown to be cross 
reactive in many species and recognizes an intense band at 46 kDa in human cerebellum tissue, as well as in 
mouse brain tissue (manufacturer data sheet).
PV. A monoclonal mouse anti-parvalbumin antibody (PV, Swant, Marly, Fribourg, Switzerland, Cat# 235, 
RRID: AB_10000343) was developed by hybridization of mouse myeloma cells with spleen cells from mice 
immunized with parvalbumin purified from carp muscles. PV labels fast-spiking GABAergic interneurons 
(FSIs)42,43,88,89.
TH. A monoclonal mouse anti-tyrosine hydroxylase antibody (TH clone lnc1, EMD Millipore, Cat# 
MAB318, RRID: AB_2201528) was developed from tyrosine hydroxylase purified from PC12 cells and recog-
nizes an epitope on the outside of the regulatory N-terminus. It detects TH in many mammalian species, includ-
ing monkey and human (manufacturer data sheet). Its use has been verified in primates90. It was used to stain 
dopamine-producing cells, located in the shell whose axons originate in the VTA, but not from the SN20,91, and in 
the core to axon projections from both the VTA and SN20.
Data availability. The data generated and analyzed during the current study are available from the corre-
sponding author on request.
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